UNDERSTANDING GIP (TIRZEPATIDE) GIP, or glucose-dependent insulinotropic polypeptide, is another natural gut hormone that plays a key role in metabolic regulation
Jastreboff, M.D., Ph.D., and Oprah Winfrey (Avid Reader Press), in Hardcover, eBook and Audio formats, available via Amazon, Barnes & Noble and Bookshop.orgAnia Jastreboff, M.D., Ph.D., Yale School of MedicineDave Knapp, "On The Pen" PodcastObesity specialist Dr
Physiological Reviews (en ingls) (The American Physiological Society) 87 (4): 1409-1439
Key limitations of current evidence include: Relatively short follow-up periods (typically 35 years) in randomised trials, whereas pancreatic cancer may take years to develop Potential for detection bias, as patients on GLP-1 therapy may undergo more frequent medical monitoring Difficulty accounting for all confounding factors in observational studies Despite these limitations, the weight of current evidence does not support a causal link between GLP-1 receptor agonist use and pancreatic cancer development

Love Employee stock.adobe.com News Study finds faster regain than ending diet programmes GLP-1 discontinuation: weight-loss drugs work until you stop Research sounds a cautionary note for short-term use without a more comprehensive approach to weight management People tend to regain weight rapidly after stopping weight-loss drugs - and faster than after ending behavioural weight loss programmes - according to a new systematic review and meta-analysis from researchers in Oxford's Nuffield Department of Primary Care Health Sciences, published in The BMJ
Two other generic Victoza options are being developed and could launch in December 2024